• Educate Phranchise™ territory owners and sales representatives through a presentation on disease state related marketing guidance to equip the sales force with a stronger scientific foundation• Built a scientific foundation for a clinical development initiative centered around new product indications using existing literature and KOL consultation.• Provide scientific and design support for leave-behind disease state information pieces directed towards patients and providers

• Proposed a clinical development plan for the New Indication Line Extension (NILEX) Lead Team outlining the competitive landscape, potential market size, and impact on the financial burden of disease to initiate discussion of a Phase III clinical trial strategy• Appraised the strength of evidence for a cardiometabolic asset in a pharmacotherapy-naïve disease state and gathered the insight of cross-functional partners to identify barriers to progress and recommend action items needed to progress the NILEX project• Developed a quick-reference presentation on the mechanism of action, clinical development timeline, and key trial data of a GLP-1 receptor agonist competitor for internal stakeholder training on the competitive treatment landscape

• Created an invoice spreadsheet template to produce an accurate recordkeeping of IDS services offered to each sponsor• Established a Standard of Procedure for the handling of intellectual property (IP) following a temperature excursion to protect the integrity of IP and maintain an accountability log• Designed a showcase deck to market IDS capabilities and fee schedule to sponsors

• Identified unmet evidence generation needs in discoid lupus erythematosus to guide publication strategy• Recommended KOLs based on sub-specialties and research interests to serve on an advisory board for clinical trial design• Contributed to a reactive slide deck to arm MSLs with concise product and clinical trial data• Conducted a literature review of the clinical, diagnostic, and treatment differences in primary and secondary Sjögren Disease (SjD) to inform medical strategy• Informed the Worldwide Medical Strategy team of the Pre-Approval Information Exchange Act to steer decisions on early payor communications

• Compound and package sterile and nonsterile products using pharmaceutical calculations and in compliance with appropriate policies

• Processed the data entry, filling, and billing of protocol orders and emergency kits from detoxification facilities• Coached externs on the dynamics of patient, prescriber, and pharmacy interactions in the Long Term Care setting• Created an alert system to detect medications with upcoming expiration dates in the detoxification supply shelf

• Conducted market research of healthcare-related agencies and consultancies to maintain an industry employer catalog for members• Adapted an industry employer catalog to define the scope and function of healthcare-related agencies and consultancies

• Compiled payer coverage data for biosimilar drugs to create an accessible database for formulary plans